ES2183841T3 - Formas de dosificacion para administrar un farmasco en una formulacion lquidid. - Google Patents

Formas de dosificacion para administrar un farmasco en una formulacion lquidid.

Info

Publication number
ES2183841T3
ES2183841T3 ES94920203T ES94920203T ES2183841T3 ES 2183841 T3 ES2183841 T3 ES 2183841T3 ES 94920203 T ES94920203 T ES 94920203T ES 94920203 T ES94920203 T ES 94920203T ES 2183841 T3 ES2183841 T3 ES 2183841T3
Authority
ES
Spain
Prior art keywords
lquidid
farmasco
administer
formulation
dosage forms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94920203T
Other languages
English (en)
Inventor
Steven D Larsen
George V Guittard
Patrick S-L Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ES2183841T3 publication Critical patent/ES2183841T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE MUESTRA UNA FORMA DE DOSIFICACION (10) PARA ENVIAR MEDICACION (22) EN UN VEHICULO NO ACUOSO A UN ENTORNO BIOLOGICO DE USO.
ES94920203T 1994-06-13 1994-06-13 Formas de dosificacion para administrar un farmasco en una formulacion lquidid. Expired - Lifetime ES2183841T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/006723 WO1995034285A1 (en) 1994-06-13 1994-06-13 Dosage form for administering drug in liquid formulation

Publications (1)

Publication Number Publication Date
ES2183841T3 true ES2183841T3 (es) 2003-04-01

Family

ID=22242671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94920203T Expired - Lifetime ES2183841T3 (es) 1994-06-13 1994-06-13 Formas de dosificacion para administrar un farmasco en una formulacion lquidid.

Country Status (11)

Country Link
EP (1) EP0768867B1 (es)
JP (1) JP3901727B2 (es)
KR (1) KR100360636B1 (es)
AT (1) ATE225647T1 (es)
AU (1) AU682703B2 (es)
CA (1) CA2185119C (es)
DE (1) DE69431533T2 (es)
DK (1) DK0768867T3 (es)
ES (1) ES2183841T3 (es)
PT (1) PT768867E (es)
WO (1) WO1995034285A1 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
WO1999019471A1 (en) 1997-10-16 1999-04-22 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with nf-at3 function
DK1112060T3 (da) * 1998-09-09 2006-04-18 Alza Corp Doseringsform anvendende flydende formulering
WO2000035419A2 (en) * 1998-12-17 2000-06-22 Alza Corporation Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
TW200418527A (en) * 2002-10-31 2004-10-01 Alza Corp Dosage form providing ascending release of liquid formulation
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
TWI615155B (zh) * 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
US20170119680A1 (en) * 2015-10-30 2017-05-04 R.P. Scherer Technologies, Llc Extended release film-coated capsules
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
DK3735228T3 (da) * 2018-03-05 2022-03-14 Amneal Complex Products Res Llc Programmerbar farmaceutiske sammensætninger til krono-lægemiddelfrigivelse
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CA3130379A1 (en) 2019-03-05 2020-09-10 Kashiv Biosciences, Llc Delayed release methylphenidate compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug

Also Published As

Publication number Publication date
JP3901727B2 (ja) 2007-04-04
WO1995034285A1 (en) 1995-12-21
EP0768867A1 (en) 1997-04-23
DE69431533D1 (de) 2002-11-14
PT768867E (pt) 2003-01-31
ATE225647T1 (de) 2002-10-15
CA2185119A1 (en) 1995-12-21
DE69431533T2 (de) 2003-10-02
CA2185119C (en) 2005-07-26
KR970703752A (ko) 1997-08-09
AU7108094A (en) 1996-01-05
JPH10501261A (ja) 1998-02-03
KR100360636B1 (ko) 2002-12-18
DK0768867T3 (da) 2002-10-28
AU682703B2 (en) 1997-10-16
EP0768867B1 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
AR240399A1 (es) Dispositivo suministrador para administrar una formulacion de agente beneficioso a un ambiente de uso.
ES2165997T3 (es) Uso de una formulacion farmaceutica pediatrica que comprende amoxicilina y clavulanato.
ES2061591T3 (es) Administracion intranasal de polipeptidos en forma pulverizada.
MX171191B (es) Composiciones farmaceuticas de glipizida
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
ES2067231T3 (es) Formas de dosificado para suministrar un agente antiparkinson.
ES2156839T1 (es) Medicamento que contiene alginato e implante para tratar la fibrosis.
FI955124A0 (fi) Protonipumppuinhibiittorin sisältävä eläinlääkeseos
DE19375061I2 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
PT814796E (pt) Uso de um farmaco r-aine numa composicao protectora para o tratamento do cancro colorectal
ES2141208T3 (es) Utilizacion de una cantidad eficaz de sustancias activas para el tratamiento de pieles mixtas.
BR9610983A (pt) Formas estáveis de administração farmacêuticas contendo paratormônio
ATE292453T1 (de) Antivirale arznei
DK1112060T3 (da) Doseringsform anvendende flydende formulering
ITMI913170A1 (it) Composizione farmaceutica per uso oftalmico contenente un antiinfiammatorio non steroideo ed un decongestionante come principi attivi
ES2160821T3 (es) Uso de una composicion que comprende amoxicilina y acido clavulanico para la produccion de un medicamento para el tratamiento de infecciones bacterianas en pacientes pediatricos.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
AR016683A1 (es) Composicion de suministro de droga solida, anhidra, proceso y uso de una pluralidad de particulas inorganicas porosas compuestas de hidroxipatita ceramicapara su preparacion.
ATE38151T1 (de) Bestaendige 5-adenosyl-l-methionin-salze enthaltende, pharmazeutische zusammensetzungen fuer orale anwendung.
YU36401A (sh) Farmaceutska kompozicija za stimulator osetljivosti na insulin sa modifikovanim ispuštanjem
ES2105605T3 (es) Antagonistas de taquiquinina, su preparacion y utilizacion en formulaciones farmaceuticas.
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
ATE525078T1 (de) Kyberdrug als autovakzine mit immunregulierenden wirkungen